Published in Cancer Weekly, April 4th, 2000
"MDXH210 is a Fab'xFab' bispecific antibody (BsAb) constructed chemically by crosslinking Fab' MAb 520C9 (anti-Her-2/neu) and Fab' MAb22 (anti-CD64)," explained L.D. Lewis and colleagues from the Dartmouth-Hitchcock Medical Center, New Hampshire, and Medarex, Inc., New Jersey, USA. "CD64 (FcgammaRI) is the high affinity membrane receptor for IgG," they added.
Lewis et al. presented data from their study at the annual meeting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.